S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Galera Therapeutics Stock Forecast, Price & News

-0.03 (-2.00%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.14 million shs
Average Volume
1.00 million shs
Market Capitalization
$38.87 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive GRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Galera Therapeutics logo

About Galera Therapeutics

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.


Galera Therapeutics (NASDAQ:GRTX) Issues Quarterly Earnings Results
November 12, 2021 |  americanbankingnews.com
Pre-market Movers: IFRX, CWBR, FUTU, MRAI, GRTX.
October 28, 2021 |  finanznachrichten.de
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
($1.63) per share


Net Income
$-74.22 million
Pretax Margin




Free Float
Market Cap
$38.87 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.04 out of 5 stars

Medical Sector

536th out of 1,391 stocks

Pharmaceutical Preparations Industry

249th out of 669 stocks

Analyst Opinion: 3.1Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Galera Therapeutics (NASDAQ:GRTX) Frequently Asked Questions

Is Galera Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Galera Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRTX, but not buy additional shares or sell existing shares.
View analyst ratings for Galera Therapeutics
or view top-rated stocks.

How has Galera Therapeutics' stock price been impacted by Coronavirus?

Galera Therapeutics' stock was trading at $10.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GRTX shares have decreased by 86.6% and is now trading at $1.47.
View which stocks have been most impacted by COVID-19

Are investors shorting Galera Therapeutics?

Galera Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 645,000 shares, a decrease of 57.6% from the October 31st total of 1,520,000 shares. Based on an average trading volume of 2,770,000 shares, the short-interest ratio is currently 0.2 days. Approximately 6.2% of the company's shares are sold short.
View Galera Therapeutics' Short Interest

When is Galera Therapeutics' next earnings date?

Galera Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Galera Therapeutics

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics, Inc. (NASDAQ:GRTX) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15.
View Galera Therapeutics' earnings history

What price target have analysts set for GRTX?

5 brokers have issued 1 year target prices for Galera Therapeutics' shares. Their forecasts range from $2.00 to $30.00. On average, they expect Galera Therapeutics' stock price to reach $14.60 in the next year. This suggests a possible upside of 893.2% from the stock's current price.
View analysts' price targets for Galera Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Galera Therapeutics' key executives?

Galera Therapeutics' management team includes the following people:
  • Dr. J. Mel Sorensen, CEO, Pres & Director (Age 64, Pay $902.25k)
  • Dr. Robert A. Beardsley, Co-Founder & COO (Age 60, Pay $627.52k)
  • Mr. Christopher Degnan, CFO & Sec. (Age 41, Pay $636.2k)
  • Mr. Joel F. Sussman, Chief Accounting Officer & Treasurer (Age 72)
  • Dr. Dennis P. Riley Ph.D., Chief Scientific Officer
  • Dr. Jon T. Holmlund, Chief Medical Officer (Age 64)
  • Mr. Arthur J. Fratamico, Chief Bus. Officer (Age 55)

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), CorMedix (CRMD), Ardelyx (ARDX), Chiasma (CHMA), (NGM), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV).

When did Galera Therapeutics IPO?

(GRTX) raised $75 million in an IPO on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

What is Galera Therapeutics' stock symbol?

Galera Therapeutics trades on the NASDAQ under the ticker symbol "GRTX."

Who are Galera Therapeutics' major shareholders?

Galera Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (7.72%), Altium Capital Management LP (1.14%), Marshall Wace LLP (0.31%), Taylor Wealth Management Partners (0.22%), Millennium Management LLC (0.14%) and Royal Bank of Canada (0.03%). Company insiders that own Galera Therapeutics stock include Bioventures Ltd Novartis, Holdings A/S Novo, Joel F Sussman, Jon T Holmlund and Linda West.
View institutional ownership trends for Galera Therapeutics

Which major investors are selling Galera Therapeutics stock?

GRTX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Marshall Wace LLP, and Taylor Wealth Management Partners.
View insider buying and selling activity for Galera Therapeutics
or view top insider-selling stocks.

Which major investors are buying Galera Therapeutics stock?

GRTX stock was purchased by a variety of institutional investors in the last quarter, including Altium Capital Management LP, AIGH Capital Management LLC, and Royal Bank of Canada.
View insider buying and selling activity for Galera Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Galera Therapeutics?

Shares of GRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galera Therapeutics' stock price today?

One share of GRTX stock can currently be purchased for approximately $1.47.

How much money does Galera Therapeutics make?

Galera Therapeutics has a market capitalization of $38.87 million. The company earns $-74.22 million in net income (profit) each year or ($3.29) on an earnings per share basis.

How many employees does Galera Therapeutics have?

Galera Therapeutics employs 38 workers across the globe.

What is Galera Therapeutics' official website?

The official website for Galera Therapeutics is www.galeratx.com.

Where are Galera Therapeutics' headquarters?

Galera Therapeutics is headquartered at 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355.

How can I contact Galera Therapeutics?

Galera Therapeutics' mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The company can be reached via phone at 610-725-1500 or via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.